Efficacy of prostaglandin E1 (alprostadil alfadex) in hemodialysis patients with peripheral arterial disease (PAD): Examination of the therapeutic effect based on measurement of skin perfusion pressure (SPP)

Efficacy of prostaglandin E1 (alprostadil alfadex) in hemodialysis patients with peripheral arterial disease (PAD): Examination of the therapeutic effect based on measurement of skin perfusion pressure (SPP) - Efficacy of prostaglandin E1 (alprostadil alfadex) in hemodialysis patients with PAD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005169

Enrollment

Registered

2011-03-03

Start date

2010-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral Arterial Disease

Interventions

Prostaglandin E1 (PGE1) injection (brand name: prostaglandin for injection, generic name: alprostadil alfadex for injection)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients aged 20 years old or older 2. Patients undergoing maintenance hemodialysis 3. No criteria regarding sex and underlying disease 4. Patients who provided written informed consent

Exclusion criteria

Exclusion criteria: 1. Patients with no symptoms of PAD (cold feeling, sense of numbness, intermittent claudication, pain during rest, etc.) 2. Patients under treatment with PGE1 3. Patients with symptoms of inflammatory, coronary artery, or cerebrovascular disease within the previous 3 months 4. Patients with severe hepatic or cardiac disease 5. Patients under treatment for a malignant tumor or those who had received treatment for a malignant tumor within the previous 5 years 6. Pregnant patients, lactating patients, patients who showed signs of pregnancy, and patients who intended to become pregnant 7. Patients with a history of hypersensitivity to PGE1 injection 8. Other patients who were judged to be inappropriate for the study

Design outcomes

Primary

Measure	Time frame
Amelioration of SPP	—

Secondary

Measure	Time frame
Results from a questionnaire survey and a visual analogue scale (VAS) Improvement of subjective symptoms, safety, and changes in blood pressure during hemodialysis	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026